Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
All content for Beyond Biotech - the podcast from Labiotech is the property of Labiotech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
Biotech royalty deals on the rise and here to stay
Beyond Biotech - the podcast from Labiotech
51 minutes
1 month ago
Biotech royalty deals on the rise and here to stay
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more than 165 transactions that have fueled breakthroughs in life sciences. In this interview we examine the evolution of alternative funding models, the ...
Beyond Biotech - the podcast from Labiotech
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it’s a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the...
